share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K：外國發行人報告
美股sec公告 ·  04/30 16:22
Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a clinical-stage biotech company, announced on April 30, 2024, its intention to apply for an order to cease being a reporting issuer in the Canadian provinces of British Columbia, Ontario, and Alberta. If approved, the company will no longer be required to file financial statements and other continuous disclosure documents with Canadian Securities Regulators. Despite this change, Clearmind will continue to meet disclosure obligations in the United States and Germany, adhering to the laws and regulations of the U.S., the Nasdaq, and the Frankfurt Stock Exchange. The company's continuous disclosure documents will remain accessible to all shareholders on its website, and Canadian shareholders will receive these documents concurrently with U.S. and German shareholders. Clearmind, which specializes in developing psychedelic-derived therapeutics for major health issues like alcohol use disorder, has a portfolio of seventeen patent families and trades on Nasdaq and the FSE under the symbols 'CMND' and 'CWYO', respectively. The company had previously voluntarily delisted from the Canadian Securities Exchange as of March 14, 2024.
Clearmind Medicine Inc., a clinical-stage biotech company, announced on April 30, 2024, its intention to apply for an order to cease being a reporting issuer in the Canadian provinces of British Columbia, Ontario, and Alberta. If approved, the company will no longer be required to file financial statements and other continuous disclosure documents with Canadian Securities Regulators. Despite this change, Clearmind will continue to meet disclosure obligations in the United States and Germany, adhering to the laws and regulations of the U.S., the Nasdaq, and the Frankfurt Stock Exchange. The company's continuous disclosure documents will remain accessible to all shareholders on its website, and Canadian shareholders will receive these documents concurrently with U.S. and German shareholders. Clearmind, which specializes in developing psychedelic-derived therapeutics for major health issues like alcohol use disorder, has a portfolio of seventeen patent families and trades on Nasdaq and the FSE under the symbols 'CMND' and 'CWYO', respectively. The company had previously voluntarily delisted from the Canadian Securities Exchange as of March 14, 2024.
處於臨床階段的生物技術公司Clearmind Medicine Inc. 於2024年4月30日宣佈，打算申請一項命令，停止在加拿大不列顛哥倫比亞省、安大略省和艾伯塔省擔任報告發行人。如果獲得批准，公司將不再需要向加拿大證券監管機構提交財務報表和其他持續披露文件。儘管有這一變化，Clearmind將繼續履行美國和德國的披露義務，遵守美國、納斯達克和法蘭克福證券交易所的法律法規。該公司的持續披露文件將可供所有股東在其網站上查閱，加拿大股東將與美國和德國股東同時收到這些文件。Clearmind專門爲酒精使用障礙等重大健康問題開發迷幻藥衍生療法，擁有十七個專利家族，在納斯達克和富時證券交易所上市，交易代碼分別爲 “CMND” 和 “CWYO”。截至2024年3月14日，該公司已自願從加拿大證券交易所退市。
處於臨床階段的生物技術公司Clearmind Medicine Inc. 於2024年4月30日宣佈，打算申請一項命令，停止在加拿大不列顛哥倫比亞省、安大略省和艾伯塔省擔任報告發行人。如果獲得批准，公司將不再需要向加拿大證券監管機構提交財務報表和其他持續披露文件。儘管有這一變化，Clearmind將繼續履行美國和德國的披露義務，遵守美國、納斯達克和法蘭克福證券交易所的法律法規。該公司的持續披露文件將可供所有股東在其網站上查閱，加拿大股東將與美國和德國股東同時收到這些文件。Clearmind專門爲酒精使用障礙等重大健康問題開發迷幻藥衍生療法，擁有十七個專利家族，在納斯達克和富時證券交易所上市，交易代碼分別爲 “CMND” 和 “CWYO”。截至2024年3月14日，該公司已自願從加拿大證券交易所退市。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息